Invizyne Technologies, designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings (NASDAQ:MDBH) has filed a registration statement on Form S-1 with SEC for the sale of its stock in a firm commitment public offering.
The offering shall be for 4.3M shares at a price per share of $4.00, for gross proceeds of $17.2M.
Invizyne has applied to list its common shares on The Nasdaq Stock Market under the ticker symbol “IZTC.”
Public Ventures will be acting as the underwriter and sole book manager for the proposed offering.
